The Communist China virus (COVID19) epidemic is raging around the world, and the elderly are a priority population for protection in various countries. On May 3, the World Health Organization (WHO) released an assessment of the Chinese vaccine, revealing the low efficacy and safety of the Chinese-made vaccine for people over 60 years of age and those with comorbidities. A number of public health experts emphasized the inadequacy of publicly available clinical data in China and the need to track vaccination responses in the elderly and to investigate and deepen the dynamics of epidemics in countries where Chinese vaccines are imported.
Low efficacy and safety of Chinese vaccines for people over 60 years of age
The WHO Strategic Advisory Group of Experts on Immunization (SAGE) published an assessment of the Chinese vaccine, stating that according to the results of the Phase III trial of the Chinese vaccine, the efficacy of protection in people over 60 years of age was assessed as “low confidence” and the safety was assessed as “very low confidence” due to insufficient data provided. “. For the Kexing vaccine, the protective efficacy was assessed as “moderate confidence” and the safety was “low confidence.
In addition, the protective efficacy and safety of the Kokosing vaccine for patients with co-morbidities and people with increased adverse health conditions were also evaluated as “very low confidence”.
China Kosin Vaccine claimed in March that vaccination in the elderly population was similar to that of the adult group. “To date, no vaccine-related abnormalities have been monitored.”
Strange dearth of data on vaccination among the elderly
The first two trials of the WHO-reported China vaccine were reportedly small-scale studies in China, and the third trial was a large-scale study in the United Arab Emirates, Egypt and Jordan, among other places. In total, the study evaluated more than 20,000 people, with only about 400 over 60 years of age.
Yokogawa, a current political commentator who worked for the Medical Research Center, noted that the lack of data on vaccination of the elderly is very strange, “Who is selecting the samples for the WHO foreign trials? Is it that Phase I and Phase II found that the elderly did not work well, and Phase III selected fewer?”
“WHO has not made the specifics of the clinical trials public. Unlike the U.S. Pfizer and Modena vaccines are always published and tracked for their effectiveness against variants of the virus.” He said, “It’s not that China doesn’t have data, because medical ethics are very loose and many experiments are done on the mainland. China itself is not even sure about the data, because once it is taken out, it may not be promoted.”
“All over the world there are more infections in the elderly, especially in nursing homes, and it’s easier to find case data than in adults. It’s very doubtful if the WHO has no evidence.” He said.
Globally, the elderly and those with underlying conditions are at high risk for COVID. Countries generally prioritize vaccination of the elderly as a priority population, expecting that priority protection will be given, allowing for a reduction in the rate of severe illness and mortality when the elderly are infected.
The situation in China is the opposite. Since the beginning of this year’s New Year’s Day, the mainland has been promoting vaccination in a high-profile manner, setting the age of the priority vaccination population at 18 to 59 years old. Gao Fu, director of the Communist Party’s CDC, admitted during the two sessions in March that Chinese vaccines are not being used in people over 60 years old.
Dr. Xiaoxu Lin, a former virology researcher at the U.S. Army Research Institute, told the Epoch Times that Gao Fu’s words effectively mean that there is no data from phase III clinical trials of the mainland vaccine for people over the age of 60, so the vaccine could not be administered to those over 60.
Lin Xiaoxu compared the Israeli and mainland vaccine trials on the elderly, “Israel’s latest vaccination with Pfizer vaccine compared data from three groups of people aged 60 to 69, 70 to 79, and 80 years old and above, and all had significant protective effects. The fact that the country is afraid to publish data related to Kexing or Sinopharm’s COVID vaccine for the elderly and patients with underlying diseases indicates that these vaccine companies and the government are still hiding something in this regard.”
Because CCP vaccine diplomacy has sufficient clinical information in many countries to make an assessment
The WHO report also noted that the Chinese vaccine is still subject to further clinical trials on the rate of protection against severe disease, duration of protection, the need for booster doses, the rate of protection against variant strains of the virus, the safety of pregnancy, the rate of protection in the elderly and in people with underlying diseases, and the monitoring of rare adverse reactions.
Hungarian doctor Garbozaga questioned on television about the Chinese vaccine, saying, “So far, the report on the Chinese vaccine is only a few hundred pages, while the report on the Pfizer vaccine is more than 20,000 pages.”
Before receiving WHO certification, the CCP had delivered Chinese domestic vaccines to 45 countries worldwide. While the CCP has not provided detailed clinical data on the vaccine to date, there is already enough clinical information and feedback in many countries to make an assessment due to the CCP’s vaccine diplomacy.
Hungary, the first country in the EU to approve the Chinese vaccine, has one of the highest mortality rates in the world based on the number of deaths from the disease as a percentage of the population. Chile and Brazil, both large recipients of the Chinese vaccine, have experienced an epidemic rebound after mass vaccination, and the death toll in Brazil has exceeded 400,000, the second highest in the world. There have also been reports of celebrities infected after receiving the Chinese vaccine, such as two bishops in Chile who were hospitalized after receiving the Chinese vaccine. The Philippine Presidential Security Guard (PSG), which received the Chinese vaccine last year, has so far tested positive for the virus in a total of 126 people. Pakistan’s president was also tested positive after the prime minister was tested positive, and both received the Chinese vaccine.
Gao Fu said at the National Conference on Vaccines and Health on April 10 this year that China’s vaccine protection rate is not very high. This statement sparked a public outcry and was reported in foreign media, but both Gao Fu and Chinese Communist Party officials later denied it, and the article was removed by Punch News, which was the first to disclose it.
Recent Comments